Ralph A. Schmid
YOU?
Author Swipe
Second Primary Cancer Among Patients With Papillary Thyroid Carcinoma Following the Chernobyl Disaster Open
Importance To our knowledge, there are no complete population-based studies of the risks of developing second malignant tumors after papillary thyroid carcinoma (PTC) in patients following the Chernobyl nuclear accident. Objective To study…
View article: Figure S3 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Figure S3 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure S3. Drug sensitivity to WEE1 inhibitors in MPM and pan-cancer cell lines with different TP53 mutational status
View article: Supplementary Tables 1-5 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Supplementary Tables 1-5 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Table S1. Human kinome sgRNA library used in this study. Supplementary Table S2. PCR primers used in this study. Supplementary Table S3. NGS data of sgRNAs in chemotherapy- and vehicle-treated MESO-1 cells. Supplementary Tabl…
View article: Figure S1 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Figure S1 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure S1. Genes regulating the G2-M cell cycle transition are deregulated in MPM.
View article: Figure S2 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Figure S2 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure S2. Prognostic significance of G2-M related genes in MPM
View article: Figure S3 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Figure S3 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure S3. Drug sensitivity to WEE1 inhibitors in MPM and pan-cancer cell lines with different TP53 mutational status
View article: Figure S5 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Figure S5 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure S5. Characterization of MPM cells that acquired resistance to chemotherapy.
View article: Figure S5 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Figure S5 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure S5. Characterization of MPM cells that acquired resistance to chemotherapy.
Data from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Malignant pleural mesothelioma (MPM) is an aggressive cancer with dismal prognosis, largely due to poor response rates to and rapid relapse after first-line pemetrexed (MTA)/cisplatin chemotherapy. A better understanding of the molecular m…
Figure S4 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure S4. WEE1 inhibitor AZD1775 synergizes with standard chemotherapy in MPM cells
Data from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Malignant pleural mesothelioma (MPM) is an aggressive cancer with dismal prognosis, largely due to poor response rates to and rapid relapse after first-line pemetrexed (MTA)/cisplatin chemotherapy. A better understanding of the molecular m…
Figure S4 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure S4. WEE1 inhibitor AZD1775 synergizes with standard chemotherapy in MPM cells
Supplementary Tables 1-5 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Table S1. Human kinome sgRNA library used in this study. Supplementary Table S2. PCR primers used in this study. Supplementary Table S3. NGS data of sgRNAs in chemotherapy- and vehicle-treated MESO-1 cells. Supplementary Tabl…
Supplementary Figure Legends and Table S6 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure Legends for S1-5 and Table S6 shows the primary antibodies used in this study.
Figure S2 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure S2. Prognostic significance of G2-M related genes in MPM
Figure S1 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure S1. Genes regulating the G2-M cell cycle transition are deregulated in MPM.
Supplementary Figure Legends and Table S6 from CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma Open
Supplementary Figure Legends for S1-5 and Table S6 shows the primary antibodies used in this study.
Supplementary Data from Patterns of Carbon-Bound Exogenous Compounds in Patients with Lung Cancer and Association with Disease Pathophysiology Open
Supplementary Data
Data from CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for <i>FGFR1</i>-Amplified Lung Cancer Open
Oncogenic activation of the FGFR pathway is frequent in lung and other cancers. However, due to drug resistance, pharmacological blockage of aberrant FGFR signaling has provided little clinical benefit in patients with FGFR-amplified tumor…
Data from CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for <i>FGFR1</i>-Amplified Lung Cancer Open
Oncogenic activation of the FGFR pathway is frequent in lung and other cancers. However, due to drug resistance, pharmacological blockage of aberrant FGFR signaling has provided little clinical benefit in patients with FGFR-amplified tumor…
Data from Patterns of Carbon-Bound Exogenous Compounds in Patients with Lung Cancer and Association with Disease Pathophysiology Open
Asymptomatic anthracosis is the accumulation of black carbon particles in adult human lungs. It is a common occurrence, but the pathophysiologic significance of anthracosis is debatable. Using in situ high mass resolution matrix-assisted l…
Supplementary Data from Patterns of Carbon-Bound Exogenous Compounds in Patients with Lung Cancer and Association with Disease Pathophysiology Open
Supplementary Data